APUS

Apimeds Pharmaceuticals US Inc

4.04

Oct 16 • 3:59 PM ET -0.35 (-7.97%)

4.10

Aftermarket • 7:59 PM ET +0.06 (1.39%)

Healthcare Drug Manufacturers - Specialty & Generic USA Nano AMEX

Peers: AYTU TXMD CPHI RMTI BGM CTOR SCYX CPIX DERM SCLX

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	6.10M
Enterprise Value	12.39M
Income	-58.17M
Sales	0.00M
Book/sh	70.54
Cash/sh	5.48
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	May 09, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.06
P/C	0.74
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.51
Current Ratio	0.51
Debt/Eq	0.14
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-36.71
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-108.46% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-1063.72%
Sales Y/Y TTM	-
EPS Q/Q	-456.18%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	62.68%
Insider Trans	0.00%
Inst Own	2.82%
Inst Trans	-
ROA	-84.20%
ROE	-100.13%
ROIC	-54.59%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-13.90%
SMA50	2.28%
SMA200	-65.46%
Trades

Shs Outstand	1.51M
Shs Float	0.56M
Short Float	14.20%
Short Ratio	0.02
Short Interest	0.08M
52W High	59.70 -93.23%
52W Low	1.51 167.55%
Volatility	14.35% 30.31%
ATR (14)	1.30
RSI (14)	47.43
Beta	-0.35
Rel Volume	0.01
Avg Volume	3.70M
Volume	43,931

Perf Week	-19.52%
Perf Month	141.92%
Perf Quarter	-37.53%
Perf Half Y	-78.51%
Perf YTD	-75.37%
Perf Year	-78.04%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	4.39
Price	4.04
Change %	-7.97%

Oct-13-26 09:43AM	NILA Token to Begin Trading on Pionex, Opening Access to Eligible Users Worldwide (GlobeNewswire) -11.15%
Oct-09-26 06:00PM	MindWave Innovations Signs 3 Client Network Agreements in 10 Days, Extending MindChain into Climate Finance, Sports Media and Insurance; Apimeds Pharmaceuticals US Provides Required NYSE American Disclosure (GlobeNewswire) -8.89%
Oct-05-26 08:00AM	MindWave Innovations Signs Agreement with US-Based BlockAssure to Build and Operate AssureChain, an End-to-End Insurance and Reinsurance Network (GlobeNewswire) +42.55%
Sep-29-26 08:30AM	MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media (GlobeNewswire) -21.44%
Sep-24-26 08:30AM	MindWave Innovations Signs Agreement to Build and Operate AQUAEChain, a Platform for Insured ALCI Credits (GlobeNewswire) +114.85%
09:00AM	Loading…
Aug-03-26 09:00AM	NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange (GlobeNewswire) -5.83%
Jul-28-26 08:30AM	MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October (GlobeNewswire) +27.19%
Jul-07-26 09:30PM	Inside the ICE House x Las Vegas: MindWave Innovations CEO Dr. Vin Menon (NYSE) -13.66%

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Matawan, NJ.

PresidentMr. Erik C. Emerson

Chief Financial OfficerMr. Erick J. Frim

Chief Operating OfficerCaptain Sandeep Singh Yadav

Chief Technology OfficerMr. Amardeep Singh

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APUS

Apimeds Pharmaceuticals US Inc

Upgrade your Finviz experience